• AcuCort reported peer-reviewed publication of results from its first Phase IV real-world study of Zeqmelit in acute allergic reactions.
• The trial indicated patients preferred the mouth-film format to corticosteroid tablets, citing easier access, higher confidence, better day-to-day usability.
• Findings suggest Zeqmelit was more likely to be carried and used as rescue treatment, supporting the product’s commercial positioning in Nordic markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief via Cision (Ref. ID: 202608110412BITN____UKPR__SV_20260811-BIT-6270-0) on August 11, 2026, and is solely responsible for the information contained therein.